IPP Bureau
Lupin Pharma Canada announces Partnership with Endoceutics
By IPP Bureau - March 09, 2021
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
NATCO receives approval for Everolimus tablets for the US market
By IPP Bureau - March 09, 2021
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Vivimed Labs receives products approvals from Uzbekistan
By IPP Bureau - March 09, 2021
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder
By IPP Bureau - March 08, 2021
Candid Powder brand is a market-leader in its category, with a market share of 64% in the medicated powder category.
Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector
By IPP Bureau - March 08, 2021
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Sun Pharma arm to acquire stake in WRS Bioproducts, Australia
By IPP Bureau - March 06, 2021
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Lupin launches penicillamine tablets USP
By IPP Bureau - March 04, 2021
Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).
COVAXIN demonstrates interim clinical efficacy of 81%
By IPP Bureau - March 04, 2021
Bharat Biotech expects to share further details of the trial results as additional data become available.
Merck FY20 sales up 8.6% euro 17.5 bn
By IPP Bureau - March 04, 2021
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
DSM increases price for polyamide 6 and 66 in EMEA
By IPP Bureau - March 02, 2021
The price increases are due to the rising costs of raw materials.
DSM secures victory in patent infringement litigation against Anhui Tiger
By IPP Bureau - March 02, 2021
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Piramal Enterprises cashing in on opportunities: ICICI Securities
By IPP Bureau - March 02, 2021
PEL will explore the PLI scheme and apply if its beneficial.
.jpg "Bayer delivers robust performance despite pandemic")
Bayer delivers robust performance despite pandemic
By IPP Bureau - February 26, 2021
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
India approves PLI scheme for pharmaceuticals
By IPP Bureau - February 26, 2021
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda
By IPP Bureau - February 26, 2021
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
